Biotechnology News and Research

RSS

Pfizer, DxS sign agreement to develop a diagnostic test kit for CDX-110 to treat patients with GBM

Pfizer Inc. and DxS (a wholly owned subsidiary of QIAGEN N.V.) today announced that they have entered into an agreement to develop a companion diagnostic test kit for PF-04948568 (CDX-110), an immunotherapy vaccine in development for the treatment of glioblastoma multiforme (GBM).

5 Feb 2010

Lux Biosciences seeks US and European marketing approval for LUVENIQ

Lux Biosciences, Inc. today announced its submission of simultaneous regulatory filings to both the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) seeking marketing approval for its investigational drug LUVENIQ™ (LX211; oral voclosporin) for the treatment of noninfectious uveitis involving the intermediate or posterior segments of the eye.

5 Feb 2010

Allergan acquires Serica Technologies

Morningside Technology Ventures, Prism VentureWorks, and Ivy Capital Partners are pleased to announce the acquisition of their portfolio company, Serica Technologies, Inc. by Allergan, Inc. Serica is a growth-stage medical device company focused on the development of biodegradable silk-based scaffolds for use in tissue regeneration in numerous therapeutic areas. Following the acquisition, Serica became a wholly owned subsidiary of Allergan.

4 Feb 2010

Arizona Oncology physicians provide advanced cancer care for MHC patients

Cancer patients in Marana now have more options for cancer care. Arizona Oncology physicians will now treat patients at Marana Healthcare Clinic (MHC). Drs. Laurie Chen and Y. Haroon Ahmad, medical oncologists, are now actively caring for patients at MHC.

4 Feb 2010

TenX Biopharma acquires exclusive global rights to zanolimumab from Genmab

TenX Biopharma, Inc. announced today it has signed a licensing agreement to acquire exclusive worldwide rights to develop and commercialize zanolimumab (HuMax-CD4®) from Genmab A/S.

4 Feb 2010

Alkermes develops proprietary LinkeRx technology platform to create injectable antipsychotics

Alkermes, Inc. today announced that it has developed a novel, proprietary LinkeRx™ technology platform to enable the creation of injectable extended-release versions of antipsychotics and other central nervous system (CNS) therapies.

4 Feb 2010

BioCryst Pharmaceuticals announces fourth-quarter and full-year 2009 financial results

BioCryst Pharmaceuticals, Inc. today announced financial results for the fourth quarter and year ended December 31, 2009.

4 Feb 2010

CTD seeks small molecule drug discovery and therapeutic antibody targets from academic researchers

A major centre created by the Medical Research Council (MRC) and MRC Technology (MRCT) in order to fast-track the discovery and development of novel drugs, opens its first call for targets today.

4 Feb 2010

Akela announces the outcomes of two legal cases involving former employees

Akela a leader in the development of therapeutics for the treatment of pain and its wholly owned subsidiary, PharmaForm, a leader in the contract pharmaceutical development and manufacturing business, today announced the outcomes of two legal cases involving former employees.

4 Feb 2010

First annual Translational Regenerative Medicine Forum in Winston-Salem

The Regenerative Medicine Foundation today announced the first annual Translational Regenerative Medicine Forum to be held April 6-8, 2010 at the Benton Convention Center in Winston-Salem.

4 Feb 2010

GEN Feb issue provides up-to-date coverage on the emerging field of epigenetics

Increasing numbers of research studies clearly demonstrate that genetics alone cannot explain the diversity of living organisms, reports Genetic Engineering & Biotechnology News (GEN).

4 Feb 2010

Helicos BioSciences to install Single Molecule and Genetic Analysis Systems at SLI and Stanford University

Helicos BioSciences Corporation today announced the completion of the sale of a Helicos® Single Molecule System to the St. Laurent Institute (SLI). The installation of the system is expected to be completed in early February.

4 Feb 2010

EUCODIS Bioscience to utilize EUR 2M capital injection for adding enzyme families and development of international markets

EUCODIS Bioscience, a company providing customized enzymes to the pharmaceutical, chemical, and other industries, announced today that it has received a cash injection of EUR 2 million from existing shareholders.

4 Feb 2010

PLX cell therapy may be an effective treatment for ischemic stroke disorder

Pluristem Therapeutics Inc. today announced that the results of a pre-clinical study in an animal model of ischemic stroke demonstrated that its PLacental eXpanded (PLX) cell therapy may be an effective treatment for this disorder.

4 Feb 2010

Brentuximab vedotin-chemotherapy combination clinical trial for Hodgkin lymphoma announced

Seattle Genetics, Inc. and Millennium Pharmaceuticals, Inc.: The Takeda Oncology Company today announced that they have initiated a phase I clinical trial of brentuximab vedotin (SGN-35) in combination with chemotherapy for the treatment of newly diagnosed Hodgkin lymphoma patients. Brentuximab vedotin is an antibody-drug conjugate (ADC) that is also in single-agent clinical trials, including a pivotal trial for relapsed and refractory Hodgkin lymphoma and a phase II trial for systemic anaplastic large cell lymphoma.

4 Feb 2010

Repligen receives USPTO Notice of Allowance for patent covering a recombinant form of Protein A

Repligen Corporation announced today that it has received a Notice of Allowance from the United States Patent and Trademark Office for a patent covering a recombinant form of Protein A which is identical in structure to the commercial form of Protein A from Staphylococcus aureus which is used in the production of many of the world's approved monoclonal antibodies. The patent, which will remain in force until 2028, covers a new Repligen proprietary product which is now available in commercial quantities.

4 Feb 2010

Phase 2a clinical trial results of VX-809 in patients with CF announced

Vertex Pharmaceuticals Incorporated today announced results from a preliminary analysis of data from a 28-day Phase 2a clinical trial of VX-809 in patients with cystic fibrosis (CF) who are homozygous for the F508del mutation.

4 Feb 2010

AMPYRA for MS: Acorda Therapeutics announces wholesale pricing and patient assistance program

Acorda Therapeutics, Inc. today announced the wholesale acquisition cost (WAC) for AMPYRA™ (dalfampridine) Extended Release Tablets will be $1,056 per 30-day supply (60-count pill bottle), an annual cost of $12,850. AMPYRA was approved on January 22, 2010 by the U.S. Food and Drug Administration (FDA) as a treatment to improve walking in patients with multiple sclerosis (MS). This was demonstrated by an increase in walking speed. AMPYRA is expected to be available in March 2010.

3 Feb 2010

Report: California biomedical industry faces unprecedented challenges

The biomedical industry is one of the most recession-resilient sectors in California's hard-hit economy and a critical driver of innovation, job growth and revenue that will help lead the state to economic recovery, according to a report released today by the California Healthcare Institute (CHI) and PricewaterhouseCoopers LLP (PwC).

3 Feb 2010

Pall launches PallSep Biotech filtration system

Pall Corporation, a global leader in filtration, separation and purification, has introduced the PallSep Biotech system for the gentle separation of target molecules from complex biotechnology process fluids.

From Pall Corporation 3 Feb 2010

Biotechnology News and Research

Pfizer, DxS sign agreement to develop a diagnostic test kit for CDX-110 to treat patients with GBM

Lux Biosciences seeks US and European marketing approval for LUVENIQ

Allergan acquires Serica Technologies

Arizona Oncology physicians provide advanced cancer care for MHC patients

TenX Biopharma acquires exclusive global rights to zanolimumab from Genmab

Alkermes develops proprietary LinkeRx technology platform to create injectable antipsychotics

BioCryst Pharmaceuticals announces fourth-quarter and full-year 2009 financial results

CTD seeks small molecule drug discovery and therapeutic antibody targets from academic researchers

Akela announces the outcomes of two legal cases involving former employees

First annual Translational Regenerative Medicine Forum in Winston-Salem

GEN Feb issue provides up-to-date coverage on the emerging field of epigenetics

Helicos BioSciences to install Single Molecule and Genetic Analysis Systems at SLI and Stanford University

EUCODIS Bioscience to utilize EUR 2M capital injection for adding enzyme families and development of international markets

PLX cell therapy may be an effective treatment for ischemic stroke disorder

Brentuximab vedotin-chemotherapy combination clinical trial for Hodgkin lymphoma announced

Repligen receives USPTO Notice of Allowance for patent covering a recombinant form of Protein A

Phase 2a clinical trial results of VX-809 in patients with CF announced

AMPYRA for MS: Acorda Therapeutics announces wholesale pricing and patient assistance program

Report: California biomedical industry faces unprecedented challenges

Pall launches PallSep Biotech filtration system

Biotechnology eBook

Achieving and maintaining ISO 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News